AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01547702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teacher Help for ADHD
Description: Teachers will review powerpoints other materials online and will have access to a study coach to assist with their understanding and practical application of the materials. Session descriptions follow:~* Session 1: Provide information about ADHD characteristics, impact, diagnosis, etiology~* Session 2: Help establish teacher's role; goal setting; introduce behaviour planning~* Session 3: Help develop and implement behaviour program specific to the needs of students with Session 2 goals~* Session 4: Help develop strategies re: classroom structure, work assignments, teacher-student relationship~* Session 5: Help to use instructional interventions for ADHD~* Session 6: Help to teach these students self-monitoring and self-evaluation skills; help teachers to evaluate progress, phase out behaviour program, and plan for relapses in unwanted behaviours
Study NCT03423719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiit-ns®
Description: Fiit-ns® is a blend of polyphenol-rich extracts from grapefruit, grape, green tea, guarana and black carrot. It also provides Vitamin B3. Daily dosage is 900 mg in two 450 mg-capsules for 16 weeks.
Study NCT03423719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product is 100% maltodextrin. Daily dosage is 900 mg in two 450 mg-capsules of identical appearance than the supplement capsule for 16 weeks.
Study NCT00313989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Evaluation of the success rate of implants
Description: Evaluation of the success rate of implants
Study NCT01048736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + Diet
Description: Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; \~10.9 kg weight loss)
Study NCT00951665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine [Kadcyla]
Description: Intravenous escalating dose
Study NCT00841854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole
Description: pantoprazole 40mg bid
Study NCT00841854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bismuth
Description: bismuth 300mg qid
Study NCT00841854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Description: metronidazole 500mg tid
Study NCT00841854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetracycline
Description: tetracycline 500mg qid
Study NCT01888380 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive, virtual autopsy
Description: Post-mortem cross-sectional imaging with CT-guided biopsy
Study NCT00951665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous escalating dose
Study NCT02754843 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phonak's equivalent newly developped power BTE
Study NCT02754843 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Equivalent competitor device
Study NCT01163864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: affect regulation training
Description: 8 sessions of a 1-hour long treatment intended to help women deal more effectively with negative affect; cognitive-behavioral smoking cessation intervention
Study NCT01163864 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: health and lifestyle
Description: 8 sessions of a 1-hour long treatment designed to help women improve their overall health; cognitive-behavioral smoking cessation intervention
Study NCT03240029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: SPP questionnaire (Self Perception Profile for Children), Systemic inventory of life quality for children (ISQV-E), Anxiety questionnaire (STAI-C), Depression questionnaire (CDI)
Study NCT01919736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait Retraining
Study NCT03147638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin, NOAC
Description: duration of treatment
Study NCT03147638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin, NOAC
Description: duration of treatment
Study NCT04150965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-TIGIT
Description: Patients with relapsed Multiple Myeloma will receive: Anti -TIGIT single agent for Cycle 1.~Each cycle is 28 days.
Study NCT01918449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical follow up by general practitioners in primary care
Description: The study evaluates two different setting to follow up patients with obstructive sleep apnea on CPAP treatment
Study NCT04086992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Description: Caregivers will be able to monitor blood pressure from home and upload in a cloud-based application on a hand-held tablet. In addition, this technology will administer surveys to the caregiver to assess for therapy side effects and adherence. Nurse-led telemedicine visits will also be utilized. The healthcare team will be able to monitor these parameters remotely.
Study NCT00790478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Study Pill (5 mg/d) taken once daily, preferably an hour before bedtime, for 12 weeks.
Study NCT00790478 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study Placebo taken once daily, preferably an hour before bedtime, for 12 weeks.
Study NCT01583816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiquimod 0.03%
Description: topical application
Study NCT01583816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiquimod 0.01%
Description: topical application
Study NCT01583816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: topical application
Study NCT03918707 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid Whole Genome Sequencing (rWGS)
Description: rWGS will be performed on blood samples from subjects in the prospective group in addition to standard of care laboratory testing and imaging studies. Blood samples will also be obtained from biological parents (if available), to determine if variants are inherited or de novo and for variant segregation.
Study NCT00768482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probuphine (buprenorphine implant)
Description: Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants)
Study NCT00768482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Buprenorphine
Description: 16 mg/day, QD
Study NCT01997190 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdV-tk + valacyclovir
Description: AdV-tk will be administered intrapleural through pleural catheter followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each AdV-tk administration.
Study NCT03048760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scans \& 1 after approx. 2 weeks of radiotherapy treatment.
Study NCT00558272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: Daily oral dose
Study NCT00558272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Study NCT02139904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine was first licensed in the UK for Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer in 1997. Vinorelbine (Navelbine®) is a semi-synthetic, third generation, vinca alkaloid. The cytotoxic effect of vinorelbine is through the disruption of mitotic spindle formation, blocking mitosis at the G2-M stage resulting in cell death.
Study NCT02139904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Active Symptom Control
Study NCT03871972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Unit
Description: 3 infusions of umbilical cord blood (UCB) unit (TNC > 2.0ⅹ107cells/kg) each 4 months apart and take oral Sirolimus (1 mg/m2/day) for 7 days (from 3 days before UCB infusion until 3 days after UCB infusion)
Study NCT04969536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched Chain Amino Acids
Description: Supplementation with 8 g Nutrex Research Amino Acid Drive BCAA in 8 ounces of water once each immediately pre-exercise and after 30 minutes of exercise
Study NCT04969536 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplementation with 2.0 milliliters of a sucralose-based drink mix with 8 ounces of water once each immediately pre-exercise and after 30 minutes of exercise
Study NCT01836393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plavina cream
Description: The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of ...%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
Study NCT02943616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorb BVS
Description: Commercially approved Absorb GT1 BVS, herein referred to as Absorb.~* Scaffold diameters: 2.5, 3.0, and 3.5 mm~* Scaffold lengths: 8, 12, 18, 23 and 28 mm~Absorb is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Study NCT00951665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine [Kadcyla]
Description: Intravenous repeating dose
Study NCT01927406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostaglandin Analog
Description: The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.
Study NCT04150965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-TIGIT + Pomalidimide + Dexamethasone
Description: Cycle 2 and beyond patients will receive Anti-TIGIT in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days..
Study NCT01888380 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional autopsy
Study NCT01160458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: 20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
Study NCT01901809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Study NCT01901809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Study NCT02745093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Women at 64-84 days' gestation will use the following dosing regimen: 200 µg mifepristone administered orally in the clinic on Day 1.
Study NCT02745093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: The client will then be given a total of 2400 µg misoprostol tablets to take home, and will be instructed to take 800 μg misoprostol administered sublingually 24-48 hours later at home and to administer a subsequent dose of 400 μg misoprostol sublingually every 3 hours up to a total of four further doses or until expulsion of the products of conception, whichever comes first.
Study NCT02142075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Study NCT02260609 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Grafix®
Description: The treatment indication is for complex diabetic foot wounds with exposed tendon and/or bone that can accommodate up to three 5cm x 5cm pieces of Grafix®.~Patients will be treated for up to 16 weeks.~Patients will be evaluated at screening and then weekly throughout the study or until wound closure.
Study NCT04885660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: compound lisinopril tablet
Description: The subjects randomly received single oral administration of compound lisinopril tablet(Lisinopril 10mg/Levamlodipine besylate 5mg)
Study NCT01927406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Description: Timolol topical eye drop will be administered in Prostaglandin Analog vs Timolol arm only, in patients with elevated intraocular pressure in both eyes.
Study NCT00988507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferroquine (SSR97193)
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT00973414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: Ringer's Lactate 8 ml/kg was given intravenously before or after CSEA in cesarean section
Study NCT00973414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Six percent hydroxyethyl starch
Description: Hydroxyethyl starch (6%) was given before or after CSEA in cesarean section
Study NCT02416102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Description: 50 mg Losartan taken orally once daily for 4 consecutive weeks.
Study NCT02416102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 50 mg
Description: 50 mg Losartan taken orally once daily for 4 consecutive weeks.
Study NCT02416102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Description: 50 mg Losartan taken orally twice daily for 4 consecutive weeks.
Study NCT02416102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 100 mg
Description: 50 mg Losartan taken orally twice daily for 4 consecutive weeks.
Study NCT01037868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive SMS text messages
Description: Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
Study NCT04266626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiotaping therapy
Description: Kinesiotaping is a new therapeutic technique that gives support to the lip and tongue base muscles without restricting range of motion or blood flow.
Study NCT00988507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT00988507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate
Description: Pharmaceutical form: tablets~Route of administration: oral
Study NCT04266626 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral motor manipulation therapy
Description: Manipulation therapy include tapping and massage of oral motor muscles including orbicularis oris and base of tongue.
Study NCT00846755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine, Propylthiouracile
Description: Drugs were titrated to render euthyroid pregnant patients with thyroid disease
Study NCT01948557 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Infant feeding counselling and support
Description: Counselling of appropriate feeding practices as recommended in WHO/UNICEF/UNAIDS guidelines on HIV and infant feeding. Subsequent intensive, home-based support of exclusive breastfeeding or safe replacement feeding according to mothers' selection of feeding practice. Counselling contacts with mothers varied over time. 1-2 antenatal contacts. After delivery, home visits by infant feeding counsellors 3-4 times in first 2 weeks then every 2 weeks until 6 months.~Outcome data collected by separate field based team who were blinded to mothers HIV status and infant feeding practice.
Study NCT01532609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMT CARE
Description: Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
Study NCT01753440 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intramyocardial implantation of of a novel mesenchymal precursor cell type (iMP).
Description: Intramyocardial implantation of a novel mesenchymal precursor cell type (iMP).
Study NCT03367416 — intervention group
Intervention type: BEHAVIORAL
Intervention: NIATx model
Description: The NIATx model engages organizations through a multi-clinic learning collaborative and coaching. NIATx teaches organizations how to implement change by using their own organization as the teaching mechanism. Key components of the model include:~1. educating executives on how to promote effective process change techniques~2. training staff teams in the theory and practice of organizational change techniques~3. training staff to develop and implement a process improvement intervention~4. implementing a sustainability plan to institutionalize change and avoid reverting to previous methods
Study NCT00813709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RNF
Description: Single dose of RNF will be administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
Study NCT00813709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RNF
Description: Single dose of RNF will be administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
Study NCT00813709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RNF
Description: Participants who were initially randomized in Study 27025 (REFLEX) to the placebo treatment group will be switched to single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
Study NCT00813709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Single dose matching placebo will be administered subcutaneously twice weekly. Placebo is supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 milliliter (mL).
Study NCT04249700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curve Sauna Dome
Description: All participants receive WBH for 80-110 minutes in an infrared sauna. Participants lay supine in the sauna during this time, and their head is external to the sauna.
Study NCT03022825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 and BCG
Description: BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.
Study NCT03022825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803 will be administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.
Study NCT04577391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Constraint-Induced Movement Therapy
Description: Children's less affected hand was restricted through a mitt with a material sewn shut on the palmar face to promote the involved side's use, and unimanual gross and fine motor activities were practiced with the more affected hand. Besides, if the participant attempted to use his/her less affected hand as an assistive, a bandage was also used to strap less affected upper limb to the trunk. Specific activities were selected according to the deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request (e.g., drawing, painting, and eating).
Study NCT04577391 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bimanual Training
Description: BIT was administrated without any restrictive material on the non-involved upper limb, but instead, children were engaged in age-appropriate gross and fine motor bimanual activities. All targeted deficits of interest were addressed within the context of the selected activity.